Background And Purpose: Disease burden of epilepsy in Hungary is underexplored. The aim of our study was to assess the quality of life and costs of adults with epilepsy.
Methods: Cross-sectional questionnaire survey was performed in two hospital based outpatient neurology centres involving consecutive patients with epilepsy. Demography, clinical characteristics, health status (EQ-5D) and health care utilisation in the past 12 months were surveyed. Cost calculation was performed from the societal perspective.
Results: Altogether 100 patients (women 58%) were involved, their mean age was 37.6 (SD = 12.5) years. Disease duration was 15.0 (SD = 12.1) years on average and 22 (22%) patients were disability pensioners. The EQ-5D score was mean 0.83 (SD = 0.24) which is significantly lower than the age-matched population norm (p = 0.017). Pain/discomfort and anxiety/depression are the most problematic health dimensions. The annual cost per patient was mean 2421 (SD = 3249) Euros (679 397 SD = 911 783 HUF; conversion: 1 Euro = 280.6 HUF), distribution between direct medical, direct non-medical and indirect costs was 33%, 18% or 49%. Patients with seizure in the past 12 months have higher cost on avergare than the asymptomatic subsample (3119 vs. 988 Euros/patient/year; 935 481 vs. 277 209 HUF/patient/year).
Conclusion: Adults with epilepsy have significantly worse health status by the EQ-5D than the gender and age matched Hungarian general population. Disease related costs are significant especially in cases with seizure, productivity loss related costs are dominant. Our study provides basic data for clinical and sustainable health care financing decisions.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Systemic Diseases in Patients with Congenital Aniridia: A Report from the Homburg Registry for Congenital Aniridia.
Ophthalmol Ther
January 2025
Dr. Rolf M. Schwiete Center for Limbal Stem Cell and Congenital Aniridia Research, Saarland University, Homburg, Saar, Germany.
Introduction: Congenital aniridia is increasingly recognized as part of a complex syndrome with numerous ocular developmental anomalies and non-ocular systemic manifestations. This requires comprehensive care and treatment of affected patients. Our purpose was to analyze systemic diseases in patients with congenital aniridia within the Homburg Aniridia Registry.
View Article and Find Full Text PDFClinical research framework proposal for ketogenic metabolic therapy in glioblastoma.
BMC Med
December 2024
Biology Department, Boston College, Chestnut Hill, MA, 02467, USA.
Article Synopsis
- Glioblastoma (GBM) is the deadliest brain tumor in adults, and current therapies are largely ineffective, which drives the need for new treatment strategies based on the tumor's metabolic needs, specifically glucose and glutamine.
- A ketogenic metabolic therapy (KMT) approach targets these metabolic pathways by combining dietary changes with specific drugs to limit glycolysis and glutaminolysis, while promoting the use of non-fermentable fuels like ketones and fatty acids.
- The glucose-ketone index (GKI) serves as a biomarker to monitor treatment effectiveness, aiming to create a more hostile environment for tumor growth and improve outcomes in GBM as well as potentially other cancer types reliant on similar metabolic pathways.
Physical exercise-mediated neuroprotective mechanisms in Parkinson's disease, Alzheimer's disease, and epilepsy.
Braz J Med Biol Res
November 2024
Rede Nacional de Neurociência e Atividade Física, Brasil.
Article Synopsis
- Physical exercise can help prevent and manage chronic diseases, significantly affecting brain function and metabolism, particularly in conditions like Parkinson's disease, Alzheimer's disease, and epilepsy.
- The review summarizes findings from a comprehensive literature search, focusing on how exercise influences neuroinflammation, neurotrophic factors, and synaptic plasticity in relation to brain health.
- It emphasizes that regular physical exercise should be considered a valuable non-drug treatment option for individuals suffering from neurological disorders.
25 years into research with the Méhes Scale, a comprehensive scale of modern dysmorphology.
Front Psychiatry
November 2024
Department of Psychiatry and Psychotherapy, Medical School, Clinical Center, University of Pécs, Pécs, Hungary.
Article Synopsis
- * It highlights the development of the Méhes Scale by Károly Méhes, which improves the categorization of MPAs compared to the previously used Waldrop Scale, allowing for better research in neuropsychiatric and neurologic disorders.
- * The review summarizes 25 years of research, showing a notable increase in MPAs, particularly in patients with schizophrenia and bipolar disorder, suggesting that MPAs may serve as identifiable traits within families affected by these conditions.
Assessing age of onset and clinical symptoms over time in patients with heterozygous pathogenic DHDDS variants.
J Inherit Metab Dis
September 2024
Department of Genetics and Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Article Synopsis
- Mono-allelic DHDDS variants lead to a range of neurological issues, including seizures, intellectual disabilities, and movement disorders, with symptoms beginning at different ages and progressing variably among patients.
- A study of 59 patients revealed that while symptoms often start early, the onset and development can differ widely, with some experiencing the full range in childhood and others in adulthood.
- No clear links were found between symptom onset or progression and factors like patient sex or specific DHDDS variants, but 19% of patients also showed signs of autism spectrum disorder, highlighting its relevance in managing the condition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!